Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

58P - Quantitative indicators of TREC and KREC excision rings in breast cancer.

Date

12 May 2023

Session

Poster viewing and lunch

Presenters

Alexander Sultanbaev

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101218-101218. 10.1016/esmoop/esmoop101218

Authors

A.V. Sultanbaev1, S. Musin2, K. Menshikov2, N. Sultanbaeva3, A. Nasretdinov3, I. Menshikova4, M. Sultanbaev4, D. Kudlay5, A. Prodeus6

Author affiliations

  • 1 Republican Clinical Oncology Dispensary - Ufa, Ufa/RU
  • 2 Republican Clinical Oncology Dispensary, Ufa/RU
  • 3 Republican Clinical Oncology Dispensary, 450054 - Ufa/RU
  • 4 BGMU - Bashkir State Medical University, Ufa/RU
  • 5 I.M. Sechenov First Moscow State Medical University, Moscow/RU
  • 6 RESEARCH CLINICAL INSTITUTE OF CHILDHOOD OF THE MOSCOW REGION, Moscow/RU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 58P

Background

The excisional rings of the T cell receptor rearrangement (TREC) and the κ-deletion element (KREC) are extrachromosomal DNA structures formed during V(D)J-recombination. A decrease in the number of TREC and KREC below age-related values may be a manifestation of immunodeficiency conditions, which can be caused by oncological and hematological diseases.

Methods

Objective: To study the change in the amount of TREC and KREC in breast cancer. Methods. For the study, blood was taken from patients with malignant neoplasms in the main group and group of healthy women of various ages. Of these 35 healthy individuals and 77 patients with breast cancer. Median age 54 years (Q1-Q3: 36-81 years). Quantification of TREC and KREC was performed by real-time PCR using the IMMUNO-BIT reagent kit (ABV-test LLC) in accordance with the instructions for the kit. DNA extraction from whole blood was performed using the AmpliPrime RIBO-prep reagent kit (NextBio LLC).

Results

According to our study, in healthy individuals, the TREC level is 75.6/105 PBMC (Q1-Q3: 19.2-135.3), the KREC level is 317.3/105 (Q1-Q3: 118.1-565.9). Whereas in patients with breast cancer, the level of TREC is 4.4/105 PBMC (Q1-Q3: 0.9-17.3), the level of KREC is 101.3/105 (Q1-Q3: 29.3-339.28). When comparing the TREC and KREC indicators in different groups, statistically significant differences were established (p<0.001, p=0.006). The levels of TREC and KREC in the healthy population were significantly higher than among patients with cancer (median TREC were 75.6 and 4.4, median KREC 317.3 and 101.3, respectively).

Conclusions

The data obtained demonstrate significant changes in T- and B-cell lymphopoiesis in patients with breast cancer. Quantitative determination of TREC and KREC makes it possible to assess the state of the T- and B-cell link of the immune system in patients with malignant neoplasms.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.